by heshamhamed | Jan 31, 2025 | News
Adoram was chosen to present to an expert panel comprising various regional stakeholders. Dr. Hesham Hamed, our Chief Scientific Officer, showcased Adoram’s business model and unique approach of utilizing allosteric small molecules to address unmet medical...
by heshamhamed | Feb 23, 2024 | News
Adoram management presented before an expert panel for the stage I venture kick startup competition. The concept of Leveraging allosteric biochemistry for patients was found convincing by the jury and was granted 10K CHF. For further details, please refer to the...
by heshamhamed | Feb 23, 2024 | News
We are heading to Sachs’ 16th Annual European Life Sciences CEO forum to discuss the latest data package generated by Adoram Therapeutics. Not only do we show superior efficacy, but more importantly improved safety compared to competitors thanks to our unique MoA....
by heshamhamed | Feb 23, 2024 | News
First day in BioEurope and everyone can already feel the enthusiasm about the market not only stabilizing but showing strong recovery trends. If you are around, let’s have a chat over a coffee. Alot of developments took place over the last year for Adoram...
by heshamhamed | Nov 1, 2022 | News
One or more representatives from Adoram Therapeutics will be attending the events listed below. Please feel free reach out via the contact form, email, or linkedin, if you would like to organize a meeting there. November: Swiss Oncology and Hematology...